GGrantIndex
Sort

326,823 grants matching clinical trial

DATA ANALYSIS AND STATISTICAL PROGRAMING SUPPORT (BASE CONTRACT) COMPANY: PROSPECTIVE GROUP

$2,279,479
Paul Converti · · N02 · FY2019 · HD

Section on Skeletal Disorders and Mineral Homeostasis

$2,279,342
Michael Collins · National Institute Of Dental & Craniofacial Research · ZIA · FY2017 · DE

Tulane COBRE for Clinical and Translational Research in Cardiometabolic Diseases

$2,279,288
Jiang He · Tulane University Of Louisiana · P20 · FY2023 · GM

Center for the Development of Phenotype-Based Treatments of Autism Spectrum Disorder

$2,279,021
David G Amaral · University Of California At Davis · P50 · FY2019 · HD

DAIT CLINICAL SITE MONITORING CENTER

$2,279,000
Mary Glessner · Ppd Development Lp · N01 · FY2015 · AI

Center for the Development of Phenotype-Based Treatments of Autism Spectrum Disorder

$2,278,831
David G Amaral · University Of California At Davis · P50 · FY2020 · HD

CTSA INFRASTRUCTURE FOR CLINICAL TRIALS

$2,278,760
David S Stephens · Emory University · UL1 · FY2010 · RR

Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE

$2,278,757
Daniel William Cramer · Brigham And Women'S Hospital · P50 · FY2007 · CA

Brain Imaging, APOE & the Preclinical Course of Alzheimer's Disease

$2,278,734
Eric M Reiman · Banner Alzheimer'S Institute · R01 · FY2017 · AG

PROTON RADIATION THERAPY RESEARCH

$2,278,576
Massachusetts General Hospital · P01 · FY2005 · CA

Clinical Trials of Biodefense Vaccines (Dengue)

$2,278,429
Kanta Subbarao · National Institute Of Allergy And Infectious Diseases · ZIA · FY2015 · AI

NEUTRALIZING ANTIBODY & AAV FIX GENE THERAPY

$2,278,426
Richard J Samulski · Univ Of North Carolina Chapel Hill · P01 · FY2017 · HL

The University of Texas MD Anderson Cancer Center SPORE in Hepatocellular Carcinoma

$2,278,344
Laura Beretta · University Of Tx Md Anderson Can Ctr · P50 · FY2022 · CA

The Ohio State University and MD Anderson Cancer Center Thyroid Cancer SPORE

$2,278,318
Matthew D Ringel · Ohio State University · P50 · FY2017 · CA

SPORE in Gl Cancer

$2,278,307
Robert J Coffey · Vanderbilt University · P50 · FY2007 · CA

SPORE in Gl Cancer

$2,278,307
Robert J Coffey · Vanderbilt University · P50 · FY2009 · CA

SPORE in Gl Cancer

$2,278,307
Robert J Coffey · Vanderbilt University · P50 · FY2008 · CA

SPORE in Gl Cancer

$2,278,307
Robert J Coffey · Vanderbilt University · P50 · FY2010 · CA

Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)

$2,278,235
Joel Moss · National Heart, Lung, And Blood Institute · ZIA · FY2015 · HL

Neutralizing Antibody & AAV FIX Gene Therapy

$2,278,230
Richard J Samulski · Univ Of North Carolina Chapel Hill · P01 · FY2014 · HL

Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer

$2,278,098
Chad A. Mirkin · Northwestern University At Chicago · U54 · FY2019 · CA

Sen-Survivors: An open-label intervention trial for frailty and senescence

$2,277,711
Gregory Armstrong · St. Jude Children'S Research Hospital · U01 · FY2020 · CA

SPORE in Prostate Cancer

$2,277,704
Donald J. Tindall · Mayo Clinic Rochester · P50 · FY2007 · CA

Sexually Transmitted Infections Clinical Trials Group: Phase II Clinical Trial for Bacterial Vaginosis

$2,277,679
Edward Hook · University Of Alabama At Birmingham · N01 · FY2018 · AI

CTSA INFRASTRUCTURE FOR CLINICAL TRIALS

$2,277,638
Harry Bernard Greenberg · Stanford University · UL1 · FY2008 · RR